Breaking News Instant updates and real-time market news.

RHHBY

Roche

$28.05

-0.27 (-0.95%)

, EXEL

Exelixis

$21.09

-1.01 (-4.57%)

14:32
04/09/18
04/09
14:32
04/09/18
14:32

Roche study of biomarker-driven therapy in mCRC suspended

A study of biomarker-driven therapy in metastatic colorectal cancer, or mCRC, sponsored by Hoffmann-La Roche (RHHBY) has been suspended "following iDMC review of cohort 4 data a temporary recruitment halt to the whole study and a temporary halt to randomisation into cohort 4 has been undertaken," according to a post to ClinicalTrials.gov. The post is being attributed as the reason for a late day move lower in shares of Exelixis (EXEL), which has dropped over 2%. In January of this year, Exelixis announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer. Reference Link

RHHBY

Roche

$28.05

-0.27 (-0.95%)

EXEL

Exelixis

$21.09

-1.01 (-4.57%)

  • 08

    May

  • 30

    May

  • 12

    Jun

RHHBY Roche
$28.05

-0.27 (-0.95%)

02/27/18
02/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stryker (SYK) upgraded to Neutral from Sell at Citi by analyst Amit Hazan, who believes supply issues at Zimmer Biomet (ZBH) could drive share gains for Stryker. 2. Chipotle (CMG) upgraded to Outperform from Neutral at Baird by analyst David Tarantino, who cited its new CEO and the potential for the company to demonstrate better sales/traffic momentum over the next 12-24 months. He believes it will support investor sentiment given the opportunity for the company to deliver strong earnings power if unit volumes begin to recover. 3. Itron (ITRI) upgraded to Buy from Hold at Cannacord Genuity by analyst Chip Moore, who said he has increased conviction in the company's forward earnings power and finds current share levels a "very compelling" entry point. He notes the stock is down 10% since the SilverSpring Networks deal announcement back in September. Moore's views the combination as compelling and has increased confidence in cost saving potential post close. 4. Winnebago (WGO) upgraded to Outperform from Market Perform at BMO Capital by analyst Gerrick Johnson, who said that the RV market growth -- currently in its 9th year -- will continue at a 10% pace, adding that the company's growth can outgain the competition because of its "operating improvement, enhanced product offering, and emerging trade-up cycle from first time buyers." The analyst also noted that Winnebago will benefit from lower corporate taxes while its stock trades at "significant" valuation discount. 5. Exelixis (EXEL) upgraded to Outperform from Perform at Oppenheimer by analyst Leah Rush Cann. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech (RHHBY) will continue to develop Cotellic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/09/18
PIPR
03/09/18
NO CHANGE
Target $170
PIPR
Overweight
Piper confident in Alexion positioning after Roche trial halt
Piper Jaffray analyst Christopher Raymond keeps an Overweight on Alexion Pharmaceuticals (ALXN) following news of a temporary trial halt for Roche's (RHHBY) Soliris/AXLN1210 challenger RO7112689 in Europe. While a bit early to write off RO7112689 as a competitive threat, the halt highlights the strength of the clinical profile for ALXN1210 and Soliris, Raymond tells investors in a research note. He remains remains confident in Alexion's positioning and bullish on the shares with a $170 price target.
03/27/18
MSCO
03/27/18
DOWNGRADE
MSCO
Underweight
Roche downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded Roche to Underweight from Equal Weight, citing the expected impact of biosimilars on margins and increasing competition in lung cancer. The analyst lowered his 2020 sales and earnings estimates and said Roche offers slower growth in terms of both the top and bottom line over 2018-2021 than large pharma peers. He cut his price target on Roche shares to CHF230 from CHF260.
04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Buy
Jefferies ponders other potential suitors for AveXis after Novartis deal
Jefferies analyst Biren Amin asks who else can jump into the mix after AveXis (AVXS) agreed to be acquired by Novartis (NVS) for $218 per share in an all-cash deal. The analyst, who does not expect anti-trust issues to arise with the deal on the table, notes the speculation that Biogen (BIIB) may need to evaluate AveXis at some point. The Novartis deal could be the "trigger that forces it to do so," Amin writes in a research note. Further, the analyst has always felt Roche (RHHBY) could have an interest in AveXis given its development program with RG7916. He points out that AveXis Chairman Dan Welch was the CEO of Intermune when Roche purchased the company in 2014 for $8.3B. AveXis in premarket trading is up 81%, or $94.14, to $210.05.
EXEL Exelixis
$21.09

-1.01 (-4.57%)

01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
02/27/18
OPCO
02/27/18
UPGRADE
OPCO
Outperform
Exelixis upgraded to Outperform from Perform at Oppenheimer
02/27/18
OPCO
02/27/18
UPGRADE
Target $40
OPCO
Outperform
Exelixis upgraded to Outperform with $40 target at Oppenheimer
Oppenheimer analyst Leah Rush Cann upgraded Exelixis to Outperform from Perform with a $40 price target. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech will continue to develop Cotellic. Cann views the company's Q4 results as "strong."

TODAY'S FREE FLY STORIES

EWW

iShares MSCI Mexico

$49.18

-0.055 (-0.11%)

06:45
08/17/18
08/17
06:45
08/17/18
06:45
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.59

-0.01 (-0.04%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$21.16

(0.00%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

, EQGP

EQT GP

$22.25

0.2 (0.91%)

06:43
08/17/18
08/17
06:43
08/17/18
06:43
Recommendations
EQT Midstream Partners, EQT GP analyst commentary  »

EQT Midstream price…

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

EQGP

EQT GP

$22.25

0.2 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$49.85

0.61 (1.24%)

06:41
08/17/18
08/17
06:41
08/17/18
06:41
Recommendations
EQT Corporation analyst commentary  »

EQT Corporation price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$15.64

0.13 (0.84%)

06:37
08/17/18
08/17
06:37
08/17/18
06:37
Initiation
Cott Corp. initiated  »

Cott Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.03

-0.0172 (-36.44%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Periodicals
MoviePass puts additional restrictions on subscribers, NY Post says »

MoviePass chief Mitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFET

Safe-T

$0.00

(0.00%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Syndicate
Safe-T raises $7.335M in a registered direct offering »

Safe-T announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.83

0.44 (1.36%)

, FB

Facebook

$174.76

-4.78 (-2.66%)

06:33
08/17/18
08/17
06:33
08/17/18
06:33
Periodicals
Twitter CEO criticizes Facebook, YouTube for Alex Jones' removal, BI reports »

Twitter (TWTR) CEO Jack…

TWTR

Twitter

$32.83

0.44 (1.36%)

FB

Facebook

$174.76

-4.78 (-2.66%)

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 06

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

AZRE

Azure Power

$15.95

-0.405 (-2.48%)

06:30
08/17/18
08/17
06:30
08/17/18
06:30
Initiation
Azure Power initiated  »

Azure Power initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

$0.00

(0.00%)

, AAPL

Apple

$213.49

3.21 (1.53%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Periodicals
Foxconn to launch semiconductor plant in China's Pearl River Delta, WSJ says »

Foxconn Technology, …

HNHPF

Hon Hai Precision

$0.00

(0.00%)

AAPL

Apple

$213.49

3.21 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMC

Yum China

$35.33

0.29 (0.83%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Downgrade
Yum China rating change  »

Yum China downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LGND

Ligand

$239.84

-7.88 (-3.18%)

06:25
08/17/18
08/17
06:25
08/17/18
06:25
Initiation
Ligand initiated  »

Ligand initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

, GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

06:24
08/17/18
08/17
06:24
08/17/18
06:24
Periodicals
Google CEO responds to criticism over plan for search engine in China, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

BXG

Bluegreen Vacations

$20.39

-0.65 (-3.09%)

06:22
08/17/18
08/17
06:22
08/17/18
06:22
Downgrade
Bluegreen Vacations rating change  »

Bluegreen Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:21
08/17/18
08/17
06:21
08/17/18
06:21
Earnings
Deere reports Q3 EPS 2.78, consensus $2.75 »

Reports Q3 worldwide net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

WMT

Walmart

$98.63

8.39 (9.30%)

, COST

Costco

$223.20

1.55 (0.70%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Walmart, Costco, Target analyst commentary  »

Walmart price target…

WMT

Walmart

$98.63

8.39 (9.30%)

COST

Costco

$223.20

1.55 (0.70%)

TGT

Target

$82.07

1.38 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Oct

KORS

Michael Kors

$71.94

0.63 (0.88%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Michael Kors analyst commentary  »

Michael Kors price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

ENB

Enbridge

$34.89

-0.19 (-0.54%)

06:18
08/17/18
08/17
06:18
08/17/18
06:18
Upgrade
Enbridge rating change  »

Enbridge upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$53.58

1.24 (2.37%)

06:17
08/17/18
08/17
06:17
08/17/18
06:17
Recommendations
Dave & Buster's analyst commentary  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:16
08/17/18
08/17
06:16
08/17/18
06:16
Hot Stocks
Deere CEO says 'continue face cost pressures for raw materials and freight' »

"Deere's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

FB

Facebook

$174.76

-4.78 (-2.66%)

06:15
08/17/18
08/17
06:15
08/17/18
06:15
Periodicals
Facebook begins to crack down on opioid dealers, TechCrunch reports »

Facebook's internal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

TM

Toyota

$122.76

0.9 (0.74%)

06:14
08/17/18
08/17
06:14
08/17/18
06:14
Periodicals
Toyota to boost production capacity in China by 20%, Reuters says »

Toyota will add more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:13
08/17/18
08/17
06:13
08/17/18
06:13
Earnings
Deere sees FY18 equipment revenue up about 30%, consensus $33.78B »

Company equipment sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

SUI

Sun Communities

06:12
08/17/18
08/17
06:12
08/17/18
06:12
Downgrade
Sun Communities rating change  »

Sun Communities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.